Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data
- PMID: 35319087
- DOI: 10.1055/a-1717-2234
Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data
Conflict of interest statement
Martin Wetzke recieved research funding not related to the submitted work from Sanofi. He furthermore reports consulting and lecturing compensations not related to the submitted work from Glaxo Smith Kline and Novartis. Monika Gappa reports consulting and lecturing compensations not related to the submitted work from Aimmune, ALK, GSK, HAL, Nestle, Novartis, and Sanofi. Christine Happle recieved research funding not related to the submitted work from Novartis and Pari. The other authors report no conflict of interest.
Comment on
-
Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo.ERJ Open Res. 2021 Aug 16;7(3):00143-2021. doi: 10.1183/23120541.00143-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34409097 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
